Associated Genetic Biomarkers
Signal transducer and activator of transcription 3 (acute-phase response factor) (STAT3) is a gene that encodes a protein that functions in transcriptional activation. Missense mutations, nonsense mutations, silent mutations, frameshift deletions, and in-frame deletions and insertions are observed in cancers such as endometrial cancer, hematopoietic and lymphoid cancers, and stomach cancer.
STAT3 is altered in 1.29% of all cancers with colon adenocarcinoma, lung adenocarcinoma, endometrial endometrioid adenocarcinoma, breast invasive ductal carcinoma, and prostate adenocarcinoma having the greatest prevalence of alterations .
The most common alterations in STAT3 are STAT3 Mutation (1.03%), STAT3 Exon 21 Mutation (0.17%), STAT3 Exon 20 Mutation (0.13%), STAT3 Amplification (0.10%), and STAT3 Loss (0.05%) .
STAT3 status serves as an inclusion eligibility criteria in 4 clinical trials, of which 2 are open and 2 are closed. Of the trials that contain STAT3 status as an inclusion criterion, 4 are phase 2 (2 open).
Trials with STAT3 status in the inclusion eligibility criteria most commonly target acute myeloid leukemia, malignant solid tumor, myelodysplastic syndrome with excess blasts-2, myeloid neoplasm, and non-small cell lung carcinoma .
The most frequent alteration to serve as an inclusion eligibility criterion is STAT3 Mutation .
Allogeneic hematopoietic stem cell transplantation, capmatinib, gefitinib, irinotecan, and liposome-encapsulated daunorubicin-cytarabine are the most frequent therapies in trials with STAT3 as an inclusion criteria .
Significance of STAT3 in Diseases
Malignant Solid Tumor +
Non-Small Cell Lung Carcinoma +
STAT3 is altered in 0.98% of non-small cell lung carcinoma patients .
STAT3 is an inclusion criterion in 1 clinical trial for non-small cell lung carcinoma, of which 0 are open and 1 is closed. Of the trial that contains STAT3 status and non-small cell lung carcinoma as inclusion criteria, 1 is phase 2 (0 open) .
Hepatocellular Carcinoma +
STAT3 is altered in 0.64% of hepatocellular carcinoma patients .
STAT3 is an inclusion criterion in 1 clinical trial for hepatocellular carcinoma, of which 1 is open and 0 are closed. Of the trial that contains STAT3 status and hepatocellular carcinoma as inclusion criteria, 1 is phase 2 (1 open) .
Acute Myeloid Leukemia +
Myeloid Neoplasm +
Myelodysplastic Syndrome With Excess Blasts-2 +
STAT3 is an inclusion criterion in 1 clinical trial for myelodysplastic syndrome with excess blasts-2, of which 1 is open and 0 are closed. Of the trial that contains STAT3 status and myelodysplastic syndrome with excess blasts-2 as inclusion criteria, 1 is phase 2 (1 open) .
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.